Literature DB >> 28571599

Patients Not Meeting PARADIGM-HF Enrollment Criteria Are Eligible for Sacubitril/Valsartan on the Basis of FDA Approval: The Need to Close the Gap.

Antonio L Perez1, Veraprapas Kittipibul1, W H Wilson Tang1, Randall C Starling2.   

Abstract

Entities:  

Keywords:  Food and Drug Administration; guidelines; heart failure; heart failure with reduced ejection fraction; sacubitril/valsartan

Mesh：

Substances：

Year:  2017        PMID： 28571599     DOI： 10.1016/j.jchf.2017.03.007

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN： 2213-1779            Impact factor:   12.035


× No keyword cloud information.
  7 in total

1.  Real-World Eligibility for Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction Patients in Korea: Data from the Korean Acute Heart Failure (KorAHF) Registry.

Authors:  Jaewon Oh; Chan Joo Lee; Jin Joo Park; Sang Eun Lee; Min-Seok Kim; Hyun-Jai Cho; Jin-Oh Choi; Hae-Young Lee; Kyung-Kuk Hwang; Kye Hun Kim; Byung-Su Yoo; Dong-Ju Choi; Sang Hong Baek; Eun-Seok Jeon; Jae-Joong Kim; Myeong-Chan Cho; Shung Chull Chae; Byung-Hee Oh; Seok-Min Kang
Journal:  Int J Heart Fail       Date:  2019-10-24

2.  Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines-Heart Failure (GWTG-HF) Registry.

Authors:  Muthiah Vaduganathan; Stephen J Greene; Shuaiqi Zhang; Maria Grau-Sepulveda; Adam D DeVore; Javed Butler; Paul A Heidenreich; Joanna C Huang; Michelle M Kittleson; Karen E Joynt Maddox; James J McDermott; Anjali Tiku Owens; Pamela N Peterson; Scott D Solomon; Orly Vardeny; Clyde W Yancy; Gregg C Fonarow
Journal:  JAMA Cardiol       Date:  2020-11-13       Impact factor: 14.676

Review 3.  Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.

Authors:  Srikanth Yandrapalli; Gabriela Andries; Medha Biswas; Sahil Khera
Journal:  Vasc Health Risk Manag       Date:  2017-10-05

4.  Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure.

Authors:  Nancy M Albert; Jason P Swindle; Erin K Buysman; Chunlan Chang
Journal:  J Am Heart Assoc       Date:  2019-05-07       Impact factor: 5.501

5.  Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort.

Authors:  Juan Carlos López-Azor; Lourdes Vicent; María Jesús Valero-Masa; Alberto Esteban-Fernández; Manuel Gómez-Bueno; Ángel Pérez; Pablo Díez-Villanueva; Javier De-Juan; Ángel Manuel-Iniesta; Ramón Bover; Susana Del Prado; Manuel Martínez-Sellés
Journal:  ESC Heart Fail       Date:  2019-11-08

6.  Eligibility of sacubitril-valsartan in a real-world heart failure population: a community-based single-centre study.

Authors:  Helena Norberg; Ellinor Bergdahl; Krister Lindmark
Journal:  ESC Heart Fail       Date:  2018-01-18

7.  Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.

Authors:  Adam D DeVore; Xiaojuan Mi; Laine Thomas; Puza P Sharma; Nancy M Albert; Javed Butler; Adrian F Hernandez; J Herbert Patterson; John A Spertus; Fredonia B Williams; Carol I Duffy; Kevin McCague; Gregg C Fonarow
Journal:  J Am Heart Assoc       Date:  2018-06-12       Impact factor: 5.501
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.